Information letter to healthcare professionals on the safe use of the medicinal product AZACITIDINE-VISTA (azacitidine). Minimization of the risk of medication errors

31.03.2026 272 views

Інформаційний лист-повідомлення до спеціалістів системи охорони здоров’я щодо безпеки застосування лікарського засобу АЗАЦИТИДИН-ВІСТА (азацитидин). Мінімізація ризику лікарських помилокPDF · 207 КБ

Завантажити

Information letter to healthcare professionals on the safe use of the medicinal product AZACITIDINE-VISTA (azacitidine). Minimization of the risk of medication errors

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to healthcare professionals on the safe use of the medicinal product AZACITIDINE-VISTA (azacitidine). Minimization of the risk of medication errors

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration